# An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

> **NCT06926985** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Jieyang People's Hospital**

## Conditions studied

- IgA Nephropathy (IgAN)

## Interventions

- **BIOLOGICAL:** anti-CD19/BCMA CAR NK cells

## Key facts

- **NCT ID:** NCT06926985
- **Lead sponsor:** Jieyang People's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-07-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to limitation of production capacity
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926985, "An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06926985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*